Did you mean: Greiner v. Wyeth, et al ?
Web Results


6 days ago ... OVERLIN et al v. WYETH LLC et al (2:18-cv-03695), New Jersey District Court, Filed: 03/16/2018 - PacerMonitor Mobile Federal and Bankruptcy Court PACER Dockets.


Saray Perez, et al. v. Wyeth Laboratories, Inc., et al. Annotate this Case. SYLLABUS. (This syllabus is not part of the opinion of the Court. It has been prepared by the Office of the Clerk for the convenience of the reader. It has been neither reviewed nor approved by the Supreme Court. Please note that, in the interests of ...


(3) and Granier et al. (14) have shown that the K. oxytoca taxon is divided into two clades. We also determined that each clade corresponds to a K. oxytoca genetic ... piperacillin (Wyeth-Lederle, Paris-La Defense, France), alone or combined with 4 μg of tazobactam (Wyeth-Lederle)/ml; cephalothin (Lilly, Suresnes, France); ...


IBDV infection (Wyeth & Cullen, 1976), but recently, very virulent IBDV strains ... ( Snyder et al., 1988). Subsequently another antigenic drift in IBDV was detected in the Delmarva area (Snyder et al., 1989) and several outbreaks of very virulent IBDV have been reported ..... (Garnier et al., 1978), it is highly probable that the.


Dec 6, 2006 ... Background. Recently, a new genetic factor within the interferon regulatory factor 5 (IRF5) gene was demonstrated for systemic lupus erythematosus (SLE) through linkage and association: the rs2004640‐T allele. IRF5 is involved in the production of rheumatoid arthritis (RA) cytokines, and SLE already ...


Jan 20, 2005 ... It was suggested, based on colony hybridization, that the β-lactamase genes of K. oxytoca could be classified into two groups (OXY-1 and OXY-2), each representing approximately half of the clin- ical isolates (12). Recently, Granier et al. (14) identified two additional sequence variants, defined as blaOXY-3.


Dec 7, 2011 ... Our review has identified a rate of occurrence ranging from 3.7% (1/27 patients) in Kanelli et al. [28] to 10.0% (9/90 patients) in Ennishi et al. [20], with other reported values in between: 4.0% (8/202 patients) in Coiffier et al. [1], 6.2% (8/ 129 patients vs 1.7%; 1/59 patients in the CHOP only arm) in Katsuya et ...


Changing R&D models in research-based pharmaceutical companies. Alexander SchuhmacherEmail author,; Oliver Gassmann and; Markus Hinder. Journal of Translational Medicine201614:105. https://doi.org/10.1186/s12967-016-0838-4. © Schuhmacher et al. 2016. Received: 24 November 2015. Accepted: 21 March ...


75010 Paris, France; kService de Biologie, Centre Hospitalier Sud Francilien, 59 Boulevard H. Dunant, 91106 Evry-Corbeil, France; lLaboratoire Statistique et ... Dequeker, T.R.R., P.V.R., L.v.d.P., A.L.-V., T.B., and E.C.R.A.F. contributed new reagents/ analytic ..... support from Wyeth, Schering-Plough, Pfizer, and Amgen. 1 .